Vitrolife AB (publ)
VTRLY
Other OTC11.00
USD
- -
- -
ISIN
US92852Y1010
CUSIP
92852Y101
Return %
Stock
S&P500
1Y
-32.89
26.53
3Y
-43.15
76.60
5Y
-57.12
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Bronwyn Brophy O'Connor
- Full Time Employees
- 1,150
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Gustaf Werners gata 2 Gothenburg Sweden 421 32
- IPO Date
- Aug 10, 2016
- Website
- vitrolife.com
- Similar Companies
- Business
- Vitrolife AB (publ) develops, manufactures and markets medical devices, consumables and genetic services for assisted reproduction and reproductive health to IVF clinics worldwide. The company offers a comprehensive portfolio of products including IVF media and oil such as G-Series and Sydney IVF media; EmbryoGlue embryo transfer medium; time-lapse incubation systems including EmbryoScope and Primo Vision with associated evaluation tools; micromanipulation pipettes; oocyte retrieval needles; sperm processing solutions; cryopreservation equipment and media; labware comprising dishes, tubes and pipettes; laser and imaging systems such as Octax; preimplantation genetic testing services; and digital witnessing systems like eWitness integrated with electronic medical records; as well as procedural solutions for vitrification, embryo transfer and temperature control. Vitrolife operates globally across Europe, Middle East and Africa; Americas; Asia-Pacific including Japan and China; and serves fertility clinics seeking to improve treatment outcomes and operational efficiency. Founded in 1989 and headquartered in Gothenburg, Sweden, the company employs approximately 1,150 people and was formerly known as Scandinavian IVF Science before changing its name in 1998. Recent developments include the May 2024 acquisition of eFertility to enhance digitalization and standardization in IVF workflows through witnessing systems and EMR integration; regulatory approvals and launches of embryoCath and ultra-rapid warm blast products; execution of a new five-year corporate strategy emphasizing R&D investment doubling, platform integration across IVF processes, growth in key markets like the US and China, and manufacturing automation; alongside Q3 2025 organic sales growth of 5% driven by Americas and EMEA performance.
Report from the Annual General Meeting of Vitrolife AB (publ)
Vitrolife AB (publ) (VTRLY) Q1 2026 Earnings Call Transcript
Vitrolife AB (publ) - Interim report Q1, 2026: Strong growth in Consumables and Technologies
Notice of the Annual General Meeting of Vitrolife AB (publ)
Vitrolife AB (publ) (VTRLY) Q4 2025 Earnings Call Transcript
Vitrolife AB (publ) - Fourth quarter and full year report 2025
Vitrolife AB (publ) (OTCMKTS:VTRLY) Shares Up 1.6% – Here’s What Happened
Vitrolife AB (publ) (OTCMKTS:VTRLY) Stock Price Down 16.4% – Should You Sell?
Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2026